Trial Profile
A Double Blind Study of CS-3150 to Evaluate Efficacy and Safety Compared to Placebo in Japanese Type 2 Diabetic Patients with Microalbuminuria (ESAX-DN study)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2023
Price :
$35
*
At a glance
- Drugs Esaxerenone (Primary)
- Indications Diabetic nephropathies
- Focus Registrational; Therapeutic Use
- Acronyms ESAX-DN
- Sponsors Daiichi Sankyo Company
- 01 Feb 2023 Results a post hoc mediation analysis of the ESAX-DN trial assessing the effect of esaxerenone on UACR reduction mediated, or not mediated, by changes in systolic BP (SBP) and/or estimated glomerular filtration rate (eGFR) published in the Hypertension Research
- 08 Nov 2019 According to a Daiichi Sankyo Company media release, results were presented during Kidney Week 2019, the annual meeting of the American Society of Nephrology,
- 08 Nov 2019 Results published in the Daiichi Sankyo Company Media Release